These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
223 related articles for article (PubMed ID: 34381351)
1. Validity Evidence for the Research Category, "Cognitively Unimpaired - Declining," as a Risk Marker for Mild Cognitive Impairment and Alzheimer's Disease. Langhough Koscik R; Hermann BP; Allison S; Clark LR; Jonaitis EM; Mueller KD; Betthauser TJ; Christian BT; Du L; Okonkwo O; Birdsill A; Chin N; Gleason C; Johnson SC Front Aging Neurosci; 2021; 13():688478. PubMed ID: 34381351 [TBL] [Abstract][Full Text] [Related]
2. Plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross-sectional and longitudinal study in the AIBL cohort. Chatterjee P; Pedrini S; Doecke JD; Thota R; Villemagne VL; Doré V; Singh AK; Wang P; Rainey-Smith S; Fowler C; Taddei K; Sohrabi HR; Molloy MP; Ames D; Maruff P; Rowe CC; Masters CL; Martins RN; Alzheimers Dement; 2023 Apr; 19(4):1117-1134. PubMed ID: 36574591 [TBL] [Abstract][Full Text] [Related]
3. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Karikari TK; Pascoal TA; Ashton NJ; Janelidze S; Benedet AL; Rodriguez JL; Chamoun M; Savard M; Kang MS; Therriault J; Schöll M; Massarweh G; Soucy JP; Höglund K; Brinkmalm G; Mattsson N; Palmqvist S; Gauthier S; Stomrud E; Zetterberg H; Hansson O; Rosa-Neto P; Blennow K Lancet Neurol; 2020 May; 19(5):422-433. PubMed ID: 32333900 [TBL] [Abstract][Full Text] [Related]
4. A Comparison of Cross-Sectional and Longitudinal Methods of Defining Objective Subtle Cognitive Decline in Preclinical Alzheimer's Disease Based on Cogstate One Card Learning Accuracy Performance. Pudumjee SB; Lundt ES; Albertson SM; Machulda MM; Kremers WK; Jack CR; Knopman DS; Petersen RC; Mielke MM; Stricker NH J Alzheimers Dis; 2021; 83(2):861-877. PubMed ID: 34366338 [TBL] [Abstract][Full Text] [Related]
5. Harnessing cognitive trajectory clusterings to examine subclinical decline risk factors. Du L; Hermann BP; Jonaitis EM; Cody KA; Rivera-Rivera L; Rowley H; Field A; Eisenmenger L; Christian BT; Betthauser TJ; Larget B; Chappell R; Janelidze S; Hansson O; Johnson SC; Langhough R Brain Commun; 2023; 5(6):fcad333. PubMed ID: 38107504 [TBL] [Abstract][Full Text] [Related]
6. Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease. Benedet AL; Leuzy A; Pascoal TA; Ashton NJ; Mathotaarachchi S; Savard M; Therriault J; Kang MS; Chamoun M; Schöll M; Zimmer ER; Gauthier S; Labbe A; Zetterberg H; Rosa-Neto P; Blennow K; Brain; 2020 Dec; 143(12):3793-3804. PubMed ID: 33210117 [TBL] [Abstract][Full Text] [Related]
7. Proper names from story recall are associated with beta-amyloid in cognitively unimpaired adults at risk for Alzheimer's disease. Mueller KD; Koscik RL; Du L; Bruno D; Jonaitis EM; Koscik AZ; Christian BT; Betthauser TJ; Chin NA; Hermann BP; Johnson SC Cortex; 2020 Oct; 131():137-150. PubMed ID: 32861209 [TBL] [Abstract][Full Text] [Related]